The U.S. Food and Drug Administration today approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected ...
U.S. FDA Approves Blue Earth Diagnostics’ Axumin™ (Fluciclovine F 18) Injection after Priority Review for PET Imaging of Recurrent Prostate Cancer - First FDA-Approved F18 PET Imaging Agent Indicated ...
A new effective PET/CT scan for prostate cancer patients can detect the location and extent of cancer that has recurred after initial treatment. Prostate PET/CT scans can detect cancer earlier than ...
BURLINGTON, Mass. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, today announced results from an investigational clinical trial ...
Loyola Medicine is the first center in the Midwest to offer the first effective PET/CT scan for prostate cancer patients. The scan can detect the location and extent of cancer that has recurred after ...
A phase 3 study from molecular imaging firm Blue Earth Diagnostics found that its Axumin contrast agent for PET scans could assist in the diagnosis of patients with glioma. Axumin, consisting of the ...
A cyclotron is a complicated device that makes very short-lived radioisotopes. These radioisotopes can be used to manufacture radiopharmaceuticals for positron emission tomography (PET) imaging. PET ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback